{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"}],"units":"Participants"}],"description":"A TEAE was defined as an event with an onset date and time on or after the first dosing start date and time, or on or after the first dosing start date if the onset time was missing. A serious TEAE was any untoward medical occurrence that at any dose results in death, prolonged hospitalization, persistent or significant disability or congenital abnormalities.","groups":[{"description":"Belinostat 1000 mg/m\\^2 administered as a 30 minute IV infusion on Days 1-5 of every 3-week cycle until disease progression or unmanageable treatment-related toxicities.","id":"OG000","title":"Belinostat"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full Analysis Dataset included all participants who received at least 1 dose of belinostat.","reportingStatus":"POSTED","timeFrame":"24 months","title":"Number of Participants With At Least One Serious Treatment-Emergent Adverse Event (TEAE)","type":"SECONDARY","unitOfMeasure":"Participants"}